Last A$1.52 AUD
Change Today -0.05 / -3.18%
Volume 355.0K
ACR On Other Exchanges
Symbol
Exchange
OTC US
As of 12:10 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

acrux ltd (ACR) Snapshot

Open
A$1.54
Previous Close
A$1.57
Day High
A$1.58
Day Low
A$1.52
52 Week High
01/31/14 - A$2.45
52 Week Low
06/6/14 - A$0.75
Market Cap
253.1M
Average Volume 10 Days
928.6K
EPS TTM
A$0.17
Shares Outstanding
166.5M
EX-Date
09/4/14
P/E TM
8.9x
Dividend
A$0.11
Dividend Yield
15.41%
Current Stock Chart for ACRUX LTD (ACR)

Related News

No related news articles were found.

acrux ltd (ACR) Related Businessweek News

No Related Businessweek News Found

acrux ltd (ACR) Details

Acrux Limited is engaged in the development and commercialization of healthcare products in Australia, Switzerland, the United States, and internationally. Its marketed products comprise Axiron for the treatment of testosterone deficiency in men; Recuvyra for pain relief of dogs; and Evamist for menopausal symptoms. The company’s product under registration study includes Estradiol MDTS for menopausal symptoms. It is also developing products, which are in formulation stage for the treatment of non-melanoma skin cancer, anti-fungal, pain and inflammation, and other diseases, as well as developing product for the treatment of animal health. The company was founded in 1998 and is headquartered in West Melbourne, Australia.

Founded in 1998

acrux ltd (ACR) Top Compensated Officers

Commercial Director
Total Annual Compensation: A$122.8K
Compensation as of Fiscal Year 2014.

acrux ltd (ACR) Key Developments

Acrux Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Acrux Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Acrux Limited Reports Earnings Results for the Year Ended June 30, 2014

Acrux Limited reported earnings results for the year ended June 30, 2014. For the period, the company reported profit was AUD 27.97 million, or 16.80 cents per share, compared to AUD 6.93 million, or 4.16 cents per share, for the year ended June 30, 2013. Revenue was AUD 53.86 million, compared to AUD 16.53 million for the year ended June 30, 2013. Profit before income tax was AUD 43.86 million, compared to AUD 10.04 million for the year ended June 30, 2013.

Acrux Limited, Annual General Meeting, Nov 27, 2014

Acrux Limited, Annual General Meeting, Nov 27, 2014., at 10:00 AUS Eastern Standard Time. Location: offices of Pitcher Partners, Level 19. Agenda: To consider the financial report of the company and the reports of the directors and auditor for the year ended 30 June 2014; to consider the adoption of remuneration report; and to consider the re-election of Ross Barrow as director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACR:AU A$1.52 AUD -0.05

ACR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Austin Engineering Ltd A$0.73 AUD -0.01
Auxilium Pharmaceuticals Inc $36.07 USD +0.21
Bradken Ltd A$2.64 AUD -1.47
Emeco Holdings Ltd A$0.12 AUD -0.005
Seven Group Holdings Ltd A$5.38 AUD -0.29
View Industry Companies
 

Industry Analysis

ACR

Industry Average

Valuation ACR Industry Range
Price/Earnings 7.9x
Price/Sales 4.1x
Price/Book 5.2x
Price/Cash Flow 7.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACRUX LTD, please visit www.acrux.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.